Log In
BCIQ
Print this Print this
 

Q203

  Manage Alerts
Collapse Summary General Information
Company Qurient Co. Ltd.
DescriptionInhibitor of Mycobacterium tuberculosis cytochrome bc1, a bacterial enzyme complex needed for respiration.
Molecular Target Mycobacterium tuberculosis cytochrome bc1
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationTuberculosis
Indication DetailsTreat extensively drug-resistant tuberculosis (XDR-TB); Treat multidrug-resistant tuberculosis (MDR-TB); Treat tuberculosis
Regulatory Designation U.S. - Orphan Drug (Treat multidrug-resistant tuberculosis (MDR-TB))
PartnerInfectex Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/17/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today